• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

急性肾损伤向慢性肾脏病转变过程中的肠道微生物群失调

Gut microbiota dysbiosis in AKI to CKD transition.

作者信息

Saranya G R, Viswanathan Pragasam

机构信息

Renal Research Lab, School of Bio Sciences and Technology, Pearl Research Park, Vellore Institute of Technology, Vellore 632014, Tamil Nadu, India.

Renal Research Lab, School of Bio Sciences and Technology, Pearl Research Park, Vellore Institute of Technology, Vellore 632014, Tamil Nadu, India.

出版信息

Biomed Pharmacother. 2023 May;161:114447. doi: 10.1016/j.biopha.2023.114447. Epub 2023 Mar 1.

DOI:10.1016/j.biopha.2023.114447
PMID:37002571
Abstract

BACKGROUND AND AIM

The symptoms of acute kidney injury (AKI) include a sudden drop-in glomerular filtration rate (GFR), a rise in serum creatinine (sCr), blood urea nitrogen (BUN), and electrolytes, which leads to a rapid loss of kidney function. Chronic kidney disease progresses when AKI symptoms persist for over three months or 90 days. Numerous prevalent secondary risk factors, including diabetes, hypertension, obesity, and heart illness, are directly or indirectly linked to the development of AKI and the switch from AKI to CKD. Recently, the change of intestinal bacteria known as "gut dysbiosis" has been linked to distant organ dysfunction, including the heart, lungs, kidneys, and brain. Indirectly or directly, gut dysbiosis contributes to the progression of CKD and AKI. However, the effects of gut dysbiosis and the mechanism of action in the progression from AKI to CKD are unknown or need further investigation. The mechanism by which gut dysbiosis initiates AKI's progression to CKD should be explicitly concerned. The review primarily focuses on the action of gut dysbiosis in kidney disease, the effects of dysbiosis, the characterisation of dysbiosis and its pathogenic products, the various pathogenic routes and mechanism involved in expediting the transition from AKI to CKD.

CONCLUSION

We identified and briefly reviewed the impacts of dysbiosis in various situations such as hypoxia, mitochondrial induced reactive oxygen species (mtROS), aryl hydrocarbon receptor (AhR) activation and microbiota derived uremic toxemic substances profoundly to push AKI to CKD conditions.

摘要

背景与目的

急性肾损伤(AKI)的症状包括肾小球滤过率(GFR)突然下降、血清肌酐(sCr)、血尿素氮(BUN)和电解质升高,这会导致肾功能迅速丧失。当AKI症状持续超过三个月或90天时,慢性肾脏病就会进展。许多常见的次要危险因素,包括糖尿病、高血压、肥胖和心脏病,都直接或间接与AKI的发生以及从AKI向CKD的转变有关。最近,被称为“肠道菌群失调”的肠道细菌变化与包括心脏、肺、肾脏和大脑在内的远处器官功能障碍有关。肠道菌群失调直接或间接地促进了CKD和AKI的进展。然而,肠道菌群失调的影响以及在从AKI进展到CKD过程中的作用机制尚不清楚或需要进一步研究。应明确关注肠道菌群失调引发AKI进展为CKD的机制。本综述主要关注肠道菌群失调在肾脏疾病中的作用、失调的影响、失调及其致病产物的特征、加速从AKI转变为CKD的各种致病途径和机制。

结论

我们识别并简要回顾了菌群失调在各种情况下的影响,如缺氧、线粒体诱导的活性氧(mtROS)、芳烃受体(AhR)激活以及微生物群衍生的尿毒症毒性物质,这些因素会深刻地促使AKI发展为CKD。

相似文献

1
Gut microbiota dysbiosis in AKI to CKD transition.急性肾损伤向慢性肾脏病转变过程中的肠道微生物群失调
Biomed Pharmacother. 2023 May;161:114447. doi: 10.1016/j.biopha.2023.114447. Epub 2023 Mar 1.
2
Dysbiosis-Related Advanced Glycation Endproducts and Trimethylamine N-Oxide in Chronic Kidney Disease.慢性肾脏病中的菌群失调相关晚期糖基化终产物和三甲胺 N-氧化物。
Toxins (Basel). 2021 May 19;13(5):361. doi: 10.3390/toxins13050361.
3
The interplay among gut microbiota, hypertension and kidney diseases: The role of short-chain fatty acids.肠道微生物群、高血压和肾脏疾病之间的相互作用:短链脂肪酸的作用。
Pharmacol Res. 2019 Mar;141:366-377. doi: 10.1016/j.phrs.2019.01.019. Epub 2019 Jan 10.
4
The Impact of CKD on Uremic Toxins and Gut Microbiota.慢性肾脏病对尿毒症毒素和肠道微生物群的影响。
Toxins (Basel). 2021 Mar 31;13(4):252. doi: 10.3390/toxins13040252.
5
The clinical impact of gut microbiota in chronic kidney disease.肠道微生物群在慢性肾脏病中的临床影响。
Korean J Intern Med. 2020 Nov;35(6):1305-1316. doi: 10.3904/kjim.2020.411. Epub 2020 Sep 29.
6
[Pathomechanism and treatment of gut microbiota dysbiosis in chronic kidney disease and interventional effects of Chinese herbal medicine].[慢性肾脏病肠道微生物群失调的发病机制、治疗及中药的干预作用]
Zhongguo Zhong Yao Za Zhi. 2017 Jul;42(13):2425-2432. doi: 10.19540/j.cnki.cjcmm.20170609.014.
7
Contribution of uremic dysbiosis to insulin resistance and sarcopenia.尿毒症性菌群失调对胰岛素抵抗和肌肉减少症的影响。
Nephrol Dial Transplant. 2020 Sep 1;35(9):1501-1517. doi: 10.1093/ndt/gfaa076.
8
Synbiotics Alleviate the Gut Indole Load and Dysbiosis in Chronic Kidney Disease.合生素可减轻慢性肾脏病患者的肠道吲哚负荷和肠道菌群失调。
Cells. 2021 Jan 9;10(1):114. doi: 10.3390/cells10010114.
9
Microbiota issue in CKD: how promising are gut-targeted approaches?慢性肾脏病中的微生物组问题:肠道靶向治疗方法有多大潜力?
J Nephrol. 2019 Feb;32(1):27-37. doi: 10.1007/s40620-018-0516-0. Epub 2018 Aug 1.
10
The Effect of ß-Glucan Prebiotic on Kidney Function, Uremic Toxins and Gut Microbiome in Stage 3 to 5 Chronic Kidney Disease (CKD) Predialysis Participants: A Randomized Controlled Trial.β-葡聚糖益生元对 3 至 5 期慢性肾脏病(CKD)透析前患者肾功能、尿毒症毒素和肠道微生物组的影响:一项随机对照试验。
Nutrients. 2022 Feb 14;14(4):805. doi: 10.3390/nu14040805.

引用本文的文献

1
Microbiota-derived corisin accelerates kidney fibrosis by promoting cellular aging.微生物群衍生的corisin通过促进细胞衰老加速肾纤维化。
Nat Commun. 2025 Aug 25;16(1):7591. doi: 10.1038/s41467-025-61847-2.
2
Association between serum lipase levels and chronic kidney disease stages.血清脂肪酶水平与慢性肾脏病分期之间的关联。
PLoS One. 2025 Aug 18;20(8):e0330329. doi: 10.1371/journal.pone.0330329. eCollection 2025.
3
Gut microbiota-derived SCFAs and MetS-related nephropathy.肠道微生物群衍生的短链脂肪酸与代谢综合征相关肾病
Front Nutr. 2025 Jul 8;12:1561271. doi: 10.3389/fnut.2025.1561271. eCollection 2025.
4
Acute kidney injury through a metabolic lens: pathological reprogramming mechanisms and clinical translation potential.从代谢角度看急性肾损伤:病理重编程机制及临床转化潜力
Front Physiol. 2025 Jun 6;16:1602865. doi: 10.3389/fphys.2025.1602865. eCollection 2025.
5
Innate immune cells in acute and chronic kidney disease.急性和慢性肾病中的固有免疫细胞。
Nat Rev Nephrol. 2025 Apr 22. doi: 10.1038/s41581-025-00958-x.
6
Characterization of gut microbiota and metabolites in renal transplant recipients during COVID-19 and prediction of one-year allograft function.新冠疫情期间肾移植受者肠道微生物群和代谢物的特征分析及移植肾一年功能预测
J Transl Med. 2025 Apr 10;23(1):420. doi: 10.1186/s12967-025-06090-5.
7
Probiotic Kefir Improves Renal Disorders in Ovariectomized Female SHR with High Fructose Intake-Induced Metabolic Syndrome.益生菌开菲尔可改善高果糖摄入诱导的代谢综合征的去卵巢雌性自发性高血压大鼠的肾脏疾病。
Probiotics Antimicrob Proteins. 2025 Mar 13. doi: 10.1007/s12602-025-10490-w.
8
Curcumin modulated gut microbiota and alleviated renal fibrosis in 5/6 nephrectomy-induced chronic kidney disease rats.姜黄素调节5/6肾切除诱导的慢性肾脏病大鼠的肠道微生物群并减轻肾纤维化。
PLoS One. 2025 Jan 9;20(1):e0314029. doi: 10.1371/journal.pone.0314029. eCollection 2025.
9
Elucidating the role of gut microbiota metabolites in diabetes by employing network pharmacology.通过网络药理学阐明肠道微生物群代谢产物在糖尿病中的作用。
Mol Med. 2024 Dec 20;30(1):263. doi: 10.1186/s10020-024-01033-0.
10
Therapeutically Induced Lymphangiogenesis Is Ineffective in Resolving Established Kidney Disease in Mice.治疗性诱导的淋巴管生成对解决小鼠已有的肾脏疾病无效。
Kidney360. 2025 Apr 1;6(4):509-520. doi: 10.34067/KID.0000000671. Epub 2024 Dec 17.